Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 5/20 | 0.71 |
| ▸ | CA6 | P23280 | 5/20 | 0.71 |
| ▸ | CA7 | P43166 | 5/20 | 0.71 |
| ▸ | CA9 | Q16790 | 5/20 | 0.71 |
| ▸ | CA14 | Q9ULX7 | 5/20 | 0.71 |
| ▸ | CA5B | Q9Y2D0 | 5/20 | 0.71 |
| ▸ | MEN1 | O00255 | 2/20 | 0.71 |
| ▸ | RECQL | P46063 | 2/20 | 0.71 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.71 |
| ▸ | CA2 | P00918 | 4/20 | 0.67 |
| ▸ | CA4 | P22748 | 4/20 | 0.67 |
| ▸ | CA5A | P35218 | 4/20 | 0.67 |
| ▸ | LMNA | P02545 | 3/20 | 0.67 |
| ▸ | CA3 | P07451 | 3/20 | 0.67 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.67 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.67 |
| ▸ | CA1 | P00915 | 2/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.67 |
| ▸ | TP53 | P04637 | 1/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL188638 | 0.86 | CA12 (0.58) | CA12CA6CA7CA9CA14 | |
| SCHEMBL5314937 | 0.84 | CA12 (1.00) | CA12CA6CA7CA9CA14 | |
| SCHEMBL15381 | 0.84 | — | — | |
| SCHEMBL3343772 | 0.81 | — | — | |
| Methylene Chloride SCHEMBL28099505 | 0.81 | CA12 (0.77) | CA12CA6CA7CA9CA14 | |
| Trientine SCHEMBL13685489 | 0.81 | CA12 (0.85) | CA12CA6CA7CA9CA14 | |
| SCHEMBL25342922 | 0.81 | CA12 (1.00) | CA12CA6CA7CA9CA14 | |
| SCHEMBL15797 | 0.81 | CA12 (1.00) | CA12CA6CA7CA9CA14 | |
| Trientine SCHEMBL15439 | 0.81 | CA12 (1.00) | CA12CA6CA7CA9CA14 | |
| SCHEMBL25340653 | 0.81 | CA12 (1.00) | CA12CA6CA7CA9CA14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 79 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100069486-A1 | ANTI-TUMOR COMPOSITION | AJINOMOTO CO., INC. (JP) | 2010-03-18 | — | — | US | claimed |
| US-20090093540-A1 | ANTI-TUMOR COMPOSITION | AJINOMOTO CO., INC. (JP) | 2009-04-09 | — | — | US | claimed |
| US-6992106-B2 | Anti-tumor composition | AJINOMOTO CO., INC. (JP) | 2006-01-31 | — | — | US | claimed |
| CN-117136242-A | Compounds, compositions and methods of treatment thereof | ITEOS比利时公司 | 2023-11-28 | — | — | CN | disclosed |
| US-20230321227-A1 | FILAMENTOUS NANOPARTICLES HAVING VACCINE ADJUVANT EFFECT | CRODA INTERNATIONAL PLC (BE) | 2023-10-12 | — | — | US | disclosed |
| EP-4176871-A1 | NANOPARTICLES, PROCESS FOR PREPARATION AND USE THEREOF AS CARRIER FOR AMPHIPATIC OF HYDRPHOBIC MOLECULES IN FIELDS OF MEDICINE INCLUDING CANCER TREATMENT AND FOOD RELATED COMPOUNDS | CANQURA ONCOLOGY AB (SE) | 2023-05-10 | — | — | EP | disclosed |
| US-20230080520-A1 | PEPTIDES COMPRISING NON-NATURAL AMINO ACIDS AND METHODS OF MAKING AND USING THE SAME | LONGEVITY BIOTECH, INC. | 2023-03-16 | — | — | US | disclosed |
| EP-3311827-B1 | NANOPARTICLES, PROCESS FOR PREPARATION AND USE THEREOF AS CARRIER FOR AMPHIPATIC OF HYDROPHOBIC MOLECULES IN FIELDS OF MEDICINE INCLUDING CANCER TREATMENT AND FOOD RELATED COMPOUNDS | CANQURA ONCOLOGY AB (SE) | 2023-01-04 | — | — | EP | disclosed |
| CN-113307829-B | Platinum (II) complex with hydroxamic acid derivative as ligand and preparation method and application thereof | 苏州科技大学 | 2022-05-24 | — | — | CN | disclosed |
| CN-114364701-A | Encapsulated protein 18 antibodies and methods of treating cancer | 加利福尼亚大学董事会 | 2022-04-15 | — | — | CN | disclosed |
| CN-114206934-A | Encapsulated protein-6 bispecific antibodies | 加利福尼亚大学董事会 | 2022-03-18 | — | — | CN | disclosed |
| EP-1068870-B1 | ANTITUMOR AGENTS | AJINOMOTO KK (JP) | 2006-06-07 | — | — | EP | disclosed |
| US-6992106-B2 | Anti-tumor composition | AJINOMOTO CO., INC. (JP) | 2006-01-31 | — | — | US | disclosed |
| WO-2005039554-A2 | THERAPEUTIC USE OF METHIONINE FOR THE TREATMENT OR PREVENTION OF MUCOSITIS | BOARD OF TRUSTEES OF SOUTHERN ILLINOIS UNIVERSITY (US) | 2005-05-06 | — | — | WO | disclosed |
| US-6462087-B1 | Anti-tumor composition | AJINOMOTO CO., INC. (JP) | 2002-10-08 | — | — | US | disclosed |
| EP-1068870-A1 | ANTITUMOR AGENTS | Ajinomoto Co., Inc. (JP) | 2001-01-17 | — | — | EP | disclosed |
| EP-1019036-A1 | USE OF D-METHIONINE TO REDUCE THE TOXICITY OF OTOTOXIC DRUGS, NOISE, AND RADIATION | Southern Illinois University (US) | 2000-07-19 | — | — | EP | disclosed |
| EP-0930877-A1 | THERAPEUTIC USE OF D-METHIONINE TO REDUCE THE TOXICITY OF PLATINUM-CONTAINING ANTI-TUMOR COMPOUNDS | Southern Illinois University (US) | 1999-07-28 | — | — | EP | disclosed |
| WO-1999017765-A1 | USE OF D-METHIONINE TO REDUCE THE TOXICITY OF OTOTOXIC DRUGS, NOISE, AND RADIATION | SOUTHERN ILLINOIS UNIVERSITY (US) | 1999-04-15 | — | — | WO | disclosed |
| WO-1998014182-A1 | THERAPEUTIC USE OF D-METHIONINE TO REDUCE THE TOXICITY OF PLATINUM-CONTAINING ANTI-TUMOR COMPOUNDS | SOUTHERN ILLINOIS UNIVERSITY (US) | 1998-04-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230080520-A1 | PEPTIDES COMPRISING NON-NATURAL AMINO ACIDS AND METHODS OF MAKING AND USING THE SAME | APLNR, SCTR, GIPR | CA12 3711/4885CA6 3359/4885CA7 4106/4885 |
| US-20100069486-A1 | ANTI-TUMOR COMPOSITION | TP53, VHL, MKI67 | CA12 36/4885CA6 470/4885CA7 127/4885 |
| US-20090093540-A1 | ANTI-TUMOR COMPOSITION | TP53, VHL, MKI67 | CA12 45/4885CA6 516/4885CA7 147/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.